Concerns about the funding commitments for OpenAI have been widely circulated this year and it appears potential creditors are worried about the company’s failure to hit ambitious internal growth targets
Australian insurance broker Steadfast Group Ltd received an indicative offer from US specialty insurance distributor Amwins Group Inc. , and private equity firm Dragoneer Investment Group LLC, that sent its shares surging by a record 36%.
Gypsy Rose Blanchard is looking back at a terrifying night. Nearly three years after her release from prison, the Life After Lock Up star reflected on the fateful night in 2015 when her...
Developing story — details emerging. Check the source link for the latest updates.
Emily Blunt's movie nights with her kids? Groundbreaking. Indeed, the Devil Wears Prada actress revealed that her films have been part of her quality time with her and husband John Krasinski's...
SpaceX is setting aside a large chunk of shares for ordinary investors as it seeks to raise a record $75 billion. Here's what to know.
The prospect of billions of dollars of oncoming demand for SpaceX stock from index-tracking funds risks creating a feedback loop that drives the shares of Elon Musk’s company even higher, academics and market observers have warned.
Rep. Thomas Massie says election fraud is real ... but not in the way most people think.
Filming a reality TV show with Jon Jones has changed Daniel Cormier's view on his longtime rival.
Apple unveiled new artificial intelligence software at WWDC, highlighted by its long-awaited update to Siri.
A personal branding expert is pushing Gen-Z to ‘act like a CEO’ to stand out in a crowded job market. Here’s how to do that.
Kurt Busch thanked everyone who had supported him since Kyle Busch's death and reflected on the times he and his brother raced together.
Researchers found that approximately 44% of GLP-1 users reported at least one side effect.
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.